(Q39750613)

14 September 2017

title

Healthcare utilization in people with postherpetic neuralgia and painful diabetic peripheral neuropathy (English)

1 reference

14 September 2017

1

Robert H Dworkin

1 reference

14 September 2017

author name string

Christopher J Panarites

2

1 reference

14 September 2017

Edward P Armstrong

3

1 reference

14 September 2017

Daniel C Malone

4

1 reference

14 September 2017

Sissi V Pham

5

1 reference

14 September 2017

language of work or name

English

0 references

publication date

1 May 2011

1 reference

Journal of the American Geriatrics Society

14 September 2017

published in

1 reference

14 September 2017

volume

59

1 reference

14 September 2017

issue

5

1 reference

14 September 2017

page(s)

827-836

1 reference

Recommendations for the Management of Herpes Zoster

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03403.X

Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03403.X

Diabetic somatic neuropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03403.X

EFNS guidelines on pharmacological treatment of neuropathic pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03403.X

Clinical characteristics and economic costs of patients with painful neuropathic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03403.X

Health care expenditure burden of persisting herpes zoster pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03403.X

Impact of postherpetic neuralgia and painful diabetic peripheral neuropathy on health care costs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03403.X

Herpes zoster burden of illness and health care resource utilisation in the Australian population aged 50 years and older.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03403.X

Medication and treatment use in primary care patients with chronic pain of predominantly neuropathic origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03403.X

Incidence rates and treatment of neuropathic pain conditions in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03403.X

A cross-sectional survey of health state impairment and treatment patterns in patients with postherpetic neuralgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03403.X

Epidemiology of refractory neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03403.X

The role of sympathetic nerve blocks in herpes zoster and postherpetic neuralgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03403.X

EFNS guidelines on neurostimulation therapy for neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03403.X

Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03403.X

Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03403.X

Modeling the effects of varicella vaccination programs on the incidence of chickenpox and shingles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03403.X

What does epidemiology tell us about risk factors for herpes zoster?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03403.X

The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03403.X

Secular trends in the epidemiology of shingles in Alberta

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03403.X

Increasing incidence of herpes zoster among Veterans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03403.X

A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03403.X

The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03403.X

Prevalence of chronic pain with neuropathic characteristics in the general population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03403.X

A cost-effectiveness comparison of desipramine, gabapentin, and pregabalin for treating postherpetic neuralgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03403.X

A cost-utility comparison of four first-line medications in painful diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03403.X

Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03403.X

10.1111/J.1532-5415.2011.03403.X

21 January 2018

Identifiers

DOI

1 reference

14 September 2017

1 reference